Blueshot Blog
Expert guides on GLP-1 medications, weight management, and healthy living
User StoriesTwo Years on a GLP-1: Does Staying on It Keep the Weight Off?
Past year one on semaglutide, I went looking for year two. STEP 5 tracked people to 104 weeks — the honest read on the average, the odds, and the catch.
NewsThe WHO Made Two Separate GLP-1 Calls in 2025
One headline said the WHO backed weight-loss drugs; another said it refused them. Both miss it: the agency made two separate 2025 calls.
LifestyleDo I Still Need Diet and Exercise on GLP-1s?
The shot quiets appetite — it doesn't pick your meals or lift your weights. Here's what the FDA and EMA labels actually say, and how to read STEP 1 honestly.
User StoriesI Stopped My GLP-1 and I'm Thinking About Restarting — Here's the Data
More than half quit a GLP-1 within a year, and many restart. What the real-world data says about stopping, weight regain, and going back at a lower dose.
Medication GuideFaster Heart Rate on a GLP-1: Expected, or a Red Flag?
A faster resting pulse on a GLP-1 is expected — semaglutide's label logs a 1-to-4-bpm rise. Here's how to tell that apart from a change worth a phone call.
Weight ManagementCan a GLP-1 Keep Prediabetes From Becoming Diabetes?
Over three years, tirzepatide sharply cut the slide from prediabetes to type 2 diabetes — but it's not an approved prevention drug, and the effect fades off it.
User StoriesDid Wegovy Break My Metabolism? What the Trials Found
I was scared the shot wrecked my metabolism and I'd gain it all back. Then I read what the trials measured on the drug. Here's what calmed me down.
Medication GuideStomach Bug or Flu on a GLP-1: When to Hold the Shot and How to Stay Hydrated
A stomach bug stacks on a gut your GLP-1 already slowed, and dehydration is the real risk. When to ask about pausing the dose, and the signs that mean call.
NewsYou Hit Your Goal Weight on a GLP-1 — Now What? Stay, Step Down, or Stop
Reaching your goal weight starts a separate decision: stay on, step down, or stop. Stop and the weight comes back; stay on and it holds. Here's the data behind each road.
User StoriesThree Months In and the Scale Won't Budge — Am I a Late Responder?
Twelve weeks on a GLP-1 and barely moved? In SURMOUNT-1, slow starters were 18% of people — and 90% of them still reached 5% by week 72. Here's the calm read.
Medication GuideMissed Your GLP-1 Shot? Take It or Skip It, by Drug, in 2026
Forgot your weekly injection? The answer depends on the drug. Wegovy, Ozempic, Mounjaro, Zepbound, and Saxenda each have their own window in the FDA label.
NewsTook Too Much GLP-1 by Accident? The Calm, Label-Based Plan for 2026
Accidentally double-dosed Ozempic or drew up too much tirzepatide from a vial? Here is the calm, label-based plan — what to do, what never to do, and when it is an emergency.
Weight ManagementMenopause Belly Fat and GLP-1s: What Wegovy Helps With, and What It Can't Touch
Midlife belly fat isn't a willpower problem — it's estrogen redistributing fat. A GLP-1 lowers weight, but it doesn't undo the hormone shift. Here's where the line sits.
LifestyleOn a GLP-1 and Tempted to Fast Harder? Read This First
The shot already quiets your appetite all week, so stacking a strict fast rarely speeds things up. Here's how to time meals, protect protein, and stay safe.
User StoriesOne Year on a GLP-1: The Honest Month-by-Month Shape of It
A first-person year on Wegovy or Ozempic — the queasy start, where the real loss lived, the plateau that wasn't failure, and why month twelve isn't a finish line.
NewsA Stronger Wegovy? What the 7.2 mg STEP UP Data Actually Says
Semaglutide 7.2 mg beat the approved 2.4 mg dose in STEP UP — 18.7% vs 15.6% weight loss. But the extra was 3.1 points, the gut effects rose, and 7.2 mg isn't approved yet.
Medication GuideTirzepatide vs. Semaglutide: What SURMOUNT-5 Settled (2026)
SURMOUNT-5 put both drugs in one trial: 20.2% vs. 13.7% weight loss at 72 weeks. The honest read on what that does — and doesn't — mean for you.
NewsCagriSema and the REDEFINE 1 Numbers: What 20.4% Actually Means
CagriSema posted 20.4% weight loss at 68 weeks in REDEFINE 1 — a large, well-controlled signal. Here's the honest read on the data, the GI tradeoff, and why it isn't here yet.